Signal Gene-editing cargo crossed the blood-brain barrier in 2025 and a $1.5 billion pact followed

Summary

The report highlights a 2025 advance in delivering therapies to the brain with exosomes. Researchers showed that exosomes loaded with gene-editing tools could cross the blood–brain barrier and enter neurons. This happened without setting off an immune response, a long-standing obstacle for such treatments. The report calls it a leap forward for difficult ongoing research into Alzheimer's disease, Parkinson's disease and glioblastoma. It also points to a $1.5 billion collaboration between Eli Lilly and Evox Therapeutics as a sign that industry has taken notice. The outlook suggests that conditions in hard-to-reach tissues, including rare neurological diseases, could become more realistic drug targets.